Outcomes for childhood and adolescent mature B-cell NHL with historical treatment regimens from Europe plus middle-income countries
| Location . | Years . | Sample size, n . | Regimen basis . | MTX dose utilized, mg/m2 . | Survival analysis . | Cohort survival, % . | TRM, % . | Survival by stage/risk group . |
|---|---|---|---|---|---|---|---|---|
| BFM | 1986-1990 | 197 | BFM86 | 500 | 6-y EFS | 82 | 5 | Stages I/II, 99%; stage III LDH < 500 U/L, 85%; stage III LDH > 500 U/L, 43%; stage IV, 67% |
| BFM | 1990-1995 | 413 | BFM90 | 5000 | 6-y EFS | 89 | 3 | Stages I/II, 98%; stage III LDH < 500 U/L, 95%; stage III LDH > 500 U/L, 81%; stage IV, 73% |
| BFM | 1996-2001 | 281 | BFM95* | 1000 | 3-y EFS | 94 | 0.4 | Group R1, 94%; group R2, 94% |
| Brazil | 1998-2003 | 53 | BFM86/90 | 2000 | ∼3-y EFS | 78 | 2 | Stages I/II, 100%; stages III/IV, 74% |
| Argentina | 1994-1999 | 57 | BFM90 | 2000 | 5-y EFS | 79 | 9 | Group R1, 100%; group R2, 86%; group R3, 82%; group R4, 50% |
| Nicaragua | 1996-2003 | 53 | Unspecified | 1000 | 9-y EFS | 53 | 2 | Stage I, 100%; stage II, 71%; stage III, 55%; stage IV, 17% |
| Venezuela | 1995-2002 | 96 | LMB89 | Unmodified | 2-y EFS | 75 | 9 | Group A, 100%; group B, 76%; group C, 56% |
| South Africa | 1995-2010 | 51 | LMB89 | Unmodified | 5-y OS | 65 | NR | Stage II, 62%; stage III, 78%; stage IV, 42% |
| Northwest Africa | 2001-2004 | 119 | LMB89 | Unmodified | 3-y OS | 75 | 21 | Stages I/II, 84%; stage III, 76%; stage IV, 56% |
| Central America | 2004-2016 | 405 | BFM90 | 1000-3000 | 3-y EFS | 70 | 11 | Stages I/II, 83%; stage III, 75%; stage IV, 55% |
| Location . | Years . | Sample size, n . | Regimen basis . | MTX dose utilized, mg/m2 . | Survival analysis . | Cohort survival, % . | TRM, % . | Survival by stage/risk group . |
|---|---|---|---|---|---|---|---|---|
| BFM | 1986-1990 | 197 | BFM86 | 500 | 6-y EFS | 82 | 5 | Stages I/II, 99%; stage III LDH < 500 U/L, 85%; stage III LDH > 500 U/L, 43%; stage IV, 67% |
| BFM | 1990-1995 | 413 | BFM90 | 5000 | 6-y EFS | 89 | 3 | Stages I/II, 98%; stage III LDH < 500 U/L, 95%; stage III LDH > 500 U/L, 81%; stage IV, 73% |
| BFM | 1996-2001 | 281 | BFM95* | 1000 | 3-y EFS | 94 | 0.4 | Group R1, 94%; group R2, 94% |
| Brazil | 1998-2003 | 53 | BFM86/90 | 2000 | ∼3-y EFS | 78 | 2 | Stages I/II, 100%; stages III/IV, 74% |
| Argentina | 1994-1999 | 57 | BFM90 | 2000 | 5-y EFS | 79 | 9 | Group R1, 100%; group R2, 86%; group R3, 82%; group R4, 50% |
| Nicaragua | 1996-2003 | 53 | Unspecified | 1000 | 9-y EFS | 53 | 2 | Stage I, 100%; stage II, 71%; stage III, 55%; stage IV, 17% |
| Venezuela | 1995-2002 | 96 | LMB89 | Unmodified | 2-y EFS | 75 | 9 | Group A, 100%; group B, 76%; group C, 56% |
| South Africa | 1995-2010 | 51 | LMB89 | Unmodified | 5-y OS | 65 | NR | Stage II, 62%; stage III, 78%; stage IV, 42% |
| Northwest Africa | 2001-2004 | 119 | LMB89 | Unmodified | 3-y OS | 75 | 21 | Stages I/II, 84%; stage III, 76%; stage IV, 56% |
| Central America | 2004-2016 | 405 | BFM90 | 1000-3000 | 3-y EFS | 70 | 11 | Stages I/II, 83%; stage III, 75%; stage IV, 55% |
BFM95 data focus on regimen for risk groups R1 and R2 only, excluding risk groups R3 and R4, which received a higher dose of MTX.